Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Oct 7

PMID 39371367

Authors

David Hauser

Lorena Urda

Christopher Lang

Christian Mittelholzer

Fabian Otte

Enja Kipfer

Yuepeng Zhang

Martin Lett

Christiane Schebitz

Roman-Ulrich Muller

Wilfried Klimkait

Thomas Klimkait

Affiliations

Soon will be listed here.

Abstract

Background: Current COVID-19 vaccines primarily target the Spike protein of defined virus variants, offering limited protection against emerging variants in immunocompetent individuals. Similarly, protective immunity following natural SARS-CoV-2 infection is variable and of short duration, raising concerns about immunocompromised individuals' vaccination strategies.

Methods: This prospective multicenter study examined 66 sera from 59 immunocompromised and 451 sera from 215 immunocompetent individuals from different pandemic periods. We establish and validate a live virus-based neutralization assay to determine the virus-inactivating potential against ancestral and current SARS-CoV-2 isolates.

Results: Our virus-based neutralization assay demonstrated superior performance over surrogate neutralization assays. We found strong but transient immunity after complete vaccination schemes, with single doses providing minimum neutralization, regardless of vaccine type. Combining vaccination-induced immunity with SARS-CoV-2 infection before or after vaccination yielded higher neutralizing titers than vaccination or infection alone, consistent across both study groups. Additional doses after a full vaccination course restored neutralization levels.

Conclusions: Potentially protective SARS-CoV-2 neutralization is reliably induced in immunocompromised individuals by prior attenuation of immunosuppression. First-generation vaccines protect against various SARS-CoV-2 variants in immunocompetent individuals, with effective cross-neutralization demonstrated up to the Delta variant but largely absent for later Omicron variants. Continuous vaccine updates are necessary to address emerging SARS-CoV-2 variants.

References

Amicone M, Borges V, Alves M, Isidro J, Ze-Ze L, Duarte S . Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol Med Public Health. 2022; 10(1):142-155. PMC: 8996265. DOI: 10.1093/emph/eoac010. View

Oran D, Topol E . Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med. 2020; 173(5):362-367. PMC: 7281624. DOI: 10.7326/M20-3012. View

Breathnach A, Riley P, Cotter M, Houston A, Habibi M, Planche T . Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. J Infect. 2021; 82(4):e11-e12. PMC: 7804382. DOI: 10.1016/j.jinf.2021.01.005. View

Minskaia E, Hertzig T, Gorbalenya A, Campanacci V, Cambillau C, Canard B . Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A. 2006; 103(13):5108-13. PMC: 1458802. DOI: 10.1073/pnas.0508200103. View

Hadfield J, Megill C, Bell S, Huddleston J, Potter B, Callender C . Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018; 34(23):4121-4123. PMC: 6247931. DOI: 10.1093/bioinformatics/bty407. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Wu J, Li J, Liu J, Wang H, Zhou G, Li J . Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Lancet Infect Dis. 2023; 23(9):1020-1030. DOI: 10.1016/S1473-3099(23)00199-8. View

Zhao Z, Zhou J, Tian M, Huang M, Liu S, Xie Y . Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. Nat Commun. 2022; 13(1):4958. PMC: 9399999. DOI: 10.1038/s41467-022-32665-7. View

Sumner K, Yadav R, Noble E, Sandford R, Joshi D, Tartof S . Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024; 230(1):45-54. PMC: 11272097. DOI: 10.1093/infdis/jiae090. View

10.

Azam M, Sulistiana R, Ratnawati M, Fibriana A, Bahrudin U, Widyaningrum D . Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020; 10(1):20692. PMC: 7691365. DOI: 10.1038/s41598-020-77739-y. View

11.

Kopsidas I, Karagiannidou S, Kostaki E, Kousi D, Douka E, Sfikakis P . Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe. Trop Med Infect Dis. 2022; 7(11). PMC: 9698960. DOI: 10.3390/tropicalmed7110373. View

12.

Collier D, Ferreira I, Kotagiri P, Datir R, Lim E, Touizer E . Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021; 596(7872):417-422. PMC: 8373615. DOI: 10.1038/s41586-021-03739-1. View

13.

Chadban S, Ahn C, Axelrod D, Foster B, Kasiske B, Kher V . KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020; 104(4S1 Suppl 1):S11-S103. DOI: 10.1097/TP.0000000000003136. View

14.

Wilkinson S, Richter A, Casey A, Osman H, Mirza J, Stockton J . Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol. 2022; 8(2):veac050. PMC: 9384748. DOI: 10.1093/ve/veac050. View

15.

Abrokwa S, Muller S, Mendez-Brito A, Hanefeld J, El Bcheraoui C . Recurrent SARS-CoV-2 infections and their potential risk to public health - a systematic review. PLoS One. 2021; 16(12):e0261221. PMC: 8659325. DOI: 10.1371/journal.pone.0261221. View

16.

Jorrissen P, Schutz P, Weiand M, Vollenberg R, Schrempf I, Ochs K . Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. Front Immunol. 2021; 12:679841. PMC: 8371319. DOI: 10.3389/fimmu.2021.679841. View

17.

Tamura T, Yamasoba D, Oda Y, Ito J, Kamasaki T, Nao N . Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5. Commun Biol. 2023; 6(1):772. PMC: 10366110. DOI: 10.1038/s42003-023-05081-w. View

18.

Harvey W, Carabelli A, Jackson B, Gupta R, Thomson E, Harrison E . SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021; 19(7):409-424. PMC: 8167834. DOI: 10.1038/s41579-021-00573-0. View

19.

Altarawneh H, Chemaitelly H, Ayoub H, Tang P, Hasan M, Yassine H . Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine. 2023; 95:104734. PMC: 10404859. DOI: 10.1016/j.ebiom.2023.104734. View

20.

Chakraborty C, Bhattacharya M, Sharma A, Mallik B . Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol. 2022; 219:980-997. PMC: 9359758. DOI: 10.1016/j.ijbiomac.2022.07.254. View